260 related articles for article (PubMed ID: 14669271)
1. Short-term biologic response to withdrawal of hormone replacement therapy in patients with invasive breast carcinoma.
Prasad R; Boland GP; Cramer A; Anderson E; Knox WF; Bundred NJ
Cancer; 2003 Dec; 98(12):2539-46. PubMed ID: 14669271
[TBL] [Abstract][Full Text] [Related]
2. Biological response to hormonal manipulation in oestrogen receptor positive ductal carcinoma in situ of the breast.
Boland GP; McKeown A; Chan KC; Prasad R; Knox WF; Bundred NJ
Br J Cancer; 2003 Jul; 89(2):277-83. PubMed ID: 12865917
[TBL] [Abstract][Full Text] [Related]
3. p27KIP-1, cyclin A and cyclin D1 protein expression in ductal carcinoma in situ of the breast: p27KIP-1 correlates with hormone receptor status but not with local recurrence.
Millar EK; Tran K; Marr P; Graham PH
Pathol Int; 2007 Apr; 57(4):183-9. PubMed ID: 17316413
[TBL] [Abstract][Full Text] [Related]
4. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma.
Chen WY; Hankinson SE; Schnitt SJ; Rosner BA; Holmes MD; Colditz GA
Cancer; 2004 Oct; 101(7):1490-500. PubMed ID: 15378477
[TBL] [Abstract][Full Text] [Related]
5. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas.
Tan P; Cady B; Wanner M; Worland P; Cukor B; Magi-Galluzzi C; Lavin P; Draetta G; Pagano M; Loda M
Cancer Res; 1997 Apr; 57(7):1259-63. PubMed ID: 9102210
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of cell cycle regulator molecules in surgically resected stage I and II breast cancer.
Peters MG; Vidal Mdel C; Giménez L; Mauro L; Armanasco E; Cresta C; Bal de Kier Joffé E; Puricelli L
Oncol Rep; 2004 Nov; 12(5):1143-50. PubMed ID: 15492807
[TBL] [Abstract][Full Text] [Related]
7. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
[TBL] [Abstract][Full Text] [Related]
8. Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast.
Lee A; Park WC; Yim HW; Lee MA; Park G; Lee KY
Jpn J Clin Oncol; 2007 Sep; 37(9):708-14. PubMed ID: 17940078
[TBL] [Abstract][Full Text] [Related]
9. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
10. Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters.
Naidu R; Wahab NA; Yadav MM; Kutty MK
Oncol Rep; 2002; 9(2):409-16. PubMed ID: 11836618
[TBL] [Abstract][Full Text] [Related]
11. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.
Cornfield DB; Palazzo JP; Schwartz GF; Goonewardene SA; Kovatich AJ; Chervoneva I; Hyslop T; Schwarting R
Cancer; 2004 Jun; 100(11):2317-27. PubMed ID: 15160334
[TBL] [Abstract][Full Text] [Related]
12. Frequent overexpression of the cyclin D1 oncogene in invasive lobular carcinoma of the breast.
Oyama T; Kashiwabara K; Yoshimoto K; Arnold A; Koerner F
Cancer Res; 1998 Jul; 58(13):2876-80. PubMed ID: 9661905
[TBL] [Abstract][Full Text] [Related]
13. Bcl-2 expression on fine-needle aspirates from primary breast carcinoma: correlation with other biologic factors.
Bozzetti C; Nizzoli R; Naldi N; Guazzi A; Camisa R; Bella MA; Cocconi G
Cancer; 1999 Aug; 87(4):224-30. PubMed ID: 10455211
[TBL] [Abstract][Full Text] [Related]
14. Do we need HER-2/neu testing for all patients with primary breast carcinoma?
Taucher S; Rudas M; Mader RM; Gnant M; Dubsky P; Bachleitner T; Roka S; Fitzal F; Kandioler D; Sporn E; Friedl J; Mittlböck M; Jakesz R
Cancer; 2003 Dec; 98(12):2547-53. PubMed ID: 14669272
[TBL] [Abstract][Full Text] [Related]
15. Immunolocalization of cyclins D and E and cyclin dependent kinase (cdk) 2 and 4 in human breast carcinoma.
Sasano H; Frost AR; Saitoh R; Taniyama Y; Nagura H; Matsunaga G; Takehana K; Kimura M; Silverberg SG
Anticancer Res; 1997; 17(5A):3685-90. PubMed ID: 9413224
[TBL] [Abstract][Full Text] [Related]
16. Expression of cell cycle proteins in T1a and T1b urothelial bladder carcinoma and their value in predicting tumor progression.
Mhawech P; Greloz V; Oppikofer C; Szalay-Quinodoz I; Herrmann F
Cancer; 2004 Jun; 100(11):2367-75. PubMed ID: 15160340
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for hormone receptor-defined breast cancer in postmenopausal women.
Rosenberg LU; Einarsdóttir K; Friman EI; Wedrén S; Dickman PW; Hall P; Magnusson C
Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2482-8. PubMed ID: 17164374
[TBL] [Abstract][Full Text] [Related]
18. [Expression of ER, PR and cyclin D1 in breast infiltrating ductal carcinoma and their clinicopathological significance].
Wang ZB; Zhao P; Liu M; Li XH
Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(8):514-7. PubMed ID: 15949328
[TBL] [Abstract][Full Text] [Related]
19. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features.
Ioachim E
Int J Clin Pract; 2008 Nov; 62(11):1736-43. PubMed ID: 19143860
[TBL] [Abstract][Full Text] [Related]
20. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]